TY - JOUR
T1 - Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 Expression and IFN-γ secretion
AU - Kim, Tae S.
AU - Chung, Su W.
AU - Kim, Seung H.
AU - Kang, So N.
AU - Kang, Bok Y.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000/8/1
Y1 - 2000/8/1
N2 - Mouse fibroblasts (H-2(b)) were genetically engineered to express a co- stimulatory B7.1 and an IFN-γ (Fb/IFN-γ/B7.1). The Fb/IFN-γ/B7.1 cells were then pulsed with an ovalbumin epitope (amino acids 257-264, SIINFEKL, H- 2K(b)-restricted) as a model antigen (Fb/IFN-γ/B7.1/OVA) and tested for the induction of OVA-specific cytotoxic T lymphocytes (CTLs) in C57BL/6 mice (H- 2(b)). Genetically engineered fibroblasts lacking either IFN-γ or B7.1 were constructed and used as controls. Immunization with the Fb/IFN-γ/B7.1/OVA cells induced strong cytotoxic activity against OVA-expressing EL4 (EG7) tumor cells but not against other H-2(b) tumor cells, such as EL4, C1498, and B16F1. The magnitude of the cytotoxic response in mice with the Fb/IFN- γ/B7.1/OVA cells was significantly higher than that in mice immunized with any other cell construct. CD8+ T cells with OVA-specific cytotoxic activity were predominant in mice immunized with Fb/IFN-γ/B7.1/OVA cells. Furthermore, treatment with Fb/IFN-γ/B7.1/OVA cells significantly prolonged the survival period of EG7 tumor-bearing mice. Anti-tumor CTL immunity by the Fb/IFN-γ/B7.1/OVA cells could be induced without the help of host antigen- presenting cells, CD4+ T cells, or NK1.1+ cells. Our results suggest that fibroblasts can be genetically modified into efficient antigen-presenting cells for the induction of antigen-specific CTL response in cancer immunotherapy. (C) 2000 Wiley-Liss, Inc.
AB - Mouse fibroblasts (H-2(b)) were genetically engineered to express a co- stimulatory B7.1 and an IFN-γ (Fb/IFN-γ/B7.1). The Fb/IFN-γ/B7.1 cells were then pulsed with an ovalbumin epitope (amino acids 257-264, SIINFEKL, H- 2K(b)-restricted) as a model antigen (Fb/IFN-γ/B7.1/OVA) and tested for the induction of OVA-specific cytotoxic T lymphocytes (CTLs) in C57BL/6 mice (H- 2(b)). Genetically engineered fibroblasts lacking either IFN-γ or B7.1 were constructed and used as controls. Immunization with the Fb/IFN-γ/B7.1/OVA cells induced strong cytotoxic activity against OVA-expressing EL4 (EG7) tumor cells but not against other H-2(b) tumor cells, such as EL4, C1498, and B16F1. The magnitude of the cytotoxic response in mice with the Fb/IFN- γ/B7.1/OVA cells was significantly higher than that in mice immunized with any other cell construct. CD8+ T cells with OVA-specific cytotoxic activity were predominant in mice immunized with Fb/IFN-γ/B7.1/OVA cells. Furthermore, treatment with Fb/IFN-γ/B7.1/OVA cells significantly prolonged the survival period of EG7 tumor-bearing mice. Anti-tumor CTL immunity by the Fb/IFN-γ/B7.1/OVA cells could be induced without the help of host antigen- presenting cells, CD4+ T cells, or NK1.1+ cells. Our results suggest that fibroblasts can be genetically modified into efficient antigen-presenting cells for the induction of antigen-specific CTL response in cancer immunotherapy. (C) 2000 Wiley-Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0034256083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034256083&partnerID=8YFLogxK
U2 - 10.1002/1097-0215(20000801)87:3<427::AID-IJC18>3.0.CO;2-J
DO - 10.1002/1097-0215(20000801)87:3<427::AID-IJC18>3.0.CO;2-J
M3 - Article
C2 - 10897050
AN - SCOPUS:0034256083
SN - 0020-7136
VL - 87
SP - 427
EP - 433
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 3
ER -